“Give you those who laugh…”

Tech entrepreneur Bryan Johnson has been trying an anti-aging drug for five years. Inspired by a 2009 study that showed that the immunosuppressant rapamycin could increase the lifespan of mice by 14% and the ability of human trials in 2023, Johnson carefully adjusted his dose to optimize benefits and mitigate risks. But instead of experiencing enhanced vitality, tech entrepreneurs began to notice a series of disturbing side effects.

Johnson’s use of rapamycin, a drug originally developed for organ transplant patients, is now prevalent in anti-aging communities, resulting in a range of adverse reactions, including oral ulcers, slowing wound healing, elevated cholesterol levels and peak blood sugar. But the most shocking problem with Johnson is his continuous increase in resting heart rate, a key metric he relies on to measure recovery and sleep quality. This information on physiological indicators prompted him to reevaluate the role of rapamycin in anti-aging protocols.

Johnson revealed a major mistake in his anti-aging protocol in his recent YouTube video, and a study at Yale University questioned the use of rapamycin after he showed that it might actually speed up biological aging. The study found 16 adverse effects on epigenetic markers, raising concerns about the drug’s long-term service life. This new evidence exacerbates Johnson’s growing suspicion about the effectiveness of rapamycin.

Johnson’s passion for rapamycin took a big blow when new discoveries suggest it could backfire on his health goals. With humility, he admitted the sarcasm and joked, “I’m laughing at home, I’m laughing with you.”

Despite abandoning rapamycin, Johnson sets setbacks as strategic adjustments rather than failures, which emphasizes the importance of sharing success and failure to drive progress. “It’s not the purpose – it’s a reset,” he said, highlighting his commitment to the adaptability and transparency of pursuing the best health.